Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves

COPD Clinical Trial

— REPEAT  

Official title:

Randomized Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06181357
• Other study ID #: 87RI21_0031 (REPEAT)
• Status: Recruiting
• Phase: N/A
• Start date: May 6, 2024
• Est. completion date: June 6, 2027

Study information

• Verified date: May 2024
• Source: University Hospital, Limoges
• Contact: Thomas EGENOD, MD
• Phone: 05 55 05 68 92
• Email: thomas.egenod[@]chu-limoges.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in the quality of life. Available drug treatments have moderate efficacy whereas surgical lung volume reduction can improve exercise capacity when offered to a very selected population but at the cost of significant morbidity and mortality.

Endoscopic Lung Volume reduction with ZEPHYR® valves improves respiratory function at rest, exercise tolerance and quality of life in patients with little or no interlobar collateral ventilation.

If this technique has therefore proven its effectiveness, it is not devoid of complications and is notably responsible for pneumothorax in 27% of cases. The management of this complication is clearly codified, ranging from patient monitoring to the removal of one or more valves. It is therefore a subject of major concern for multiple reasons: high incidence, lengthening of hospital stay, increase in the overall cost of care, potential loss of benefit for the patient in the event of permanent withdrawal. valves and above all a potentially fatal event.

A new strategy for implanting ZEPHYR® valves in two stages has been developed in Limoges University Hospital. This innovative algorithm has been evaluated in several non-comparative single or multicenter studies. In those studies, pneumothorax' rate secondary to lung volume reduction with endobronchial valves is rated between 4.5 and 12%. The efficacy of the treatment appears to be comparable with the data found in the trials evaluating in which the entire lobe was treated in one procedure. Moreover, despite two procedures, there does not seem to be any increased risk of occurrence of other complications. Finally, the systematic scheduling of a thoracic computed tomography between the two procedures showed that 26.6% of patients presented a reduction in volume greater than 350mL despite incomplete treatment.

These data seem promising but no direct comparison with standard one-step treatment has ever been conducted so far.

Description:

The Zephyr® valve was first implanted in 2001. Since then, 5 important studies have proven a clinical superiority compared to the existing standard of care. Bronchoscopic lung-volume reduction with the use of one-way endobronchial valves is a potential treatment for patients with severe emphysema. Loss of lung elastic recoil leads to airflow obstruction, gas trapping, and increased operating lung volumes. Lung volume reduction surgery (LVRS), resection of the most affected of the lung, has been clearly shown to improve outcomes in selected patient groups. The surgical intervention is, however, associated with significant morbidity and an early mortality rate of about 5%. Therefore, there is considerable interest in developing novel treatment approaches that can reduce lung volume and gas trapping, either more safely than LVRS or in patients for whom LVRS is not an option.

In the present study, 244 patients will be randomized. After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. Half of them, the experimental group, will be treated according to Limoges' treatment algorithm (2 stages). For the other half, the control group, the entire lobe will be treated during one procedure will. Both groups will receive the standard of care treatments, according to the Global initiative for chronic Obstructive Lung Disease recommendations (GOLD).

Both groups will be followed for one year:

• All the patients will undergo a thorax CT scan 45 days after implanting the last valve. Three follow-up consultations are planned at 45 days, 6, and 12 months. During these consultations, each patient will complete a Saint-George Respiratory Questionnaire (SGRQ) Test, a plethysmography and a 6-minutes walking test.

• Patients randomized in the experimental group will undergo a plethysmography and a thorax CT scan one day before the second procedure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 244
• Est. completion date: June 6, 2027
• Est. primary completion date: June 6, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

Patient able to give informed consent and participate in the study

• Age = 35 years old and = 75 years old at the time of signing the consent

• Emphysema (homogeneous or heterogeneous) on a recent CT scan (< 6 months). Heterogeneous emphysema defined by a difference of at least 15% destruction (threshold 910HU) between two adjacent lobes.

• Destruction = 50% (threshold 910 HU) of the target lobe on the chest scanner

• Smoking quit for 3 months

• Dyspnea = 2 according to the modified Medical Research Council (mMRC) questionnaire)

• Post-bronchodilator FEV between 15 and 50% theoretical

• Post-bronchodilator total lung capacity = 100% theoretical and post-bronchodilator residual volume = 175% theoretical

• Distance traveled during the TM6M = 100m

• Member of or beneficiary of a social security scheme

Exclusion Criteria:

• Asthma considered as main diagnosis

• BMI < 18 kg/m2

• Recurrent exacerbations: (>3 over the last year or 2 requiring hospitalization)

• Myocardial infarction or stroke in the 6 months prior to inclusion

• Symptoms of heart failure in the 6 months prior to inclusion

• Chest CT abnormalities: giant bulla (occupying more than a third of the pulmonary field), paraseptal emphysema, pulmonary nodule greater than 0.8cm (not applicable pulmonary nodules known for more than a year and stable), fibrosing interstitial pneumonitis, dilated bronchi

• Pulmonary tomoscintigraphy:

• Patients for whom the least perfused lobe is not the one with the highest emphysema destruction score

• Patients with homogeneous emphysema for whom the perfusion delta (difference in perfusion between the ipsilateral lung and the treated lobe) is less than 10%

• Arterial blood gas analysis in ambient air: Hypoxemia in ambient air (PaO2 < 45 mmHg). Hypercapnia (PaCO2 > 55 mmHg)

• Echocardiography:

• Left Ventricular Ejection Function < 45%

• Systolic pulmonary arterial pressure > 45 mmHg

• History of pneumonectomy, lung surgery homolateral to the lobe targeted for endoscopic lung volume reduction

• History of pneumothorax homolateral to the lobe targeted for endoscopic lung volume reduction

• History of endoscopic volume reduction

• Oral corticosteroid therapy > 20 mg/day within the 4 weeks preceding inclusion

• Symptomatic bronchial dilatations, bronchial colonization with pseudomonas aeruginosa, multi-resistant bacteria or aspergillus origin

• Metastatic cancer undergoing treatment or whose treatments ended less than 5 years ago

• Pregnant or breastfeeding women

• Nickel allergy

• Patient under guardianship, curatorship or under judicial protection

• Participation in another interventional clinical research

• Any other condition which, in the opinion of the investigator, could interfere with the objective of the study or would cause the subject's participation in the study to be suboptimal, in particular (non-exhaustive list) unweaned alcoholism, substance abuse, non-compliance with usual follow-up visits)

secondary exclusion criteria:

• Evidence of collateral ventilation measured by the Chartis system

Related Conditions & MeSH terms

• COPD
• Emphysema
• Pneumothorax
• Pulmonary Emphysema

Intervention

Procedure:
• Endoscopic lung volume reduction in 2 stages
After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
• Endoscopic lung volume reduction in 1 stage
After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux
France	CHU de Brest	Brest
France	CHU de Dijon	Dijon
France	chu de Grenoble	Grenoble
France	CHU de Lille	Lille
France	CHU de Limoges	Limoges
France	APHM	Marseille
France	Hopital Saint Joseph	Marseille
France	CHU de Nice	Nice
France	APHP	Paris
France	APHP	Paris
France	CHU de Rouen	Rouen
France	chu de Strasbourg	Strasbourg
France	Hopital Foch	Suresnes
France	chu de Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pneumothorax rate	Proportion of patients suffering from at least one pneumothorax rate between the beginning and the first 45 days following the end of lung volume reduction with ZEPHYR® valves	45 day
Secondary	Forced expiratory volume in one second (FEV1) measurement	Functional parameters at rest (plethysmography) - assessment of FEV1 in liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Force Vital Expiratory (FVE) measurement	Functional parameters at rest (plethysmography) - assessment of FVE in Liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Functional Residual Capacity (FRC) measurement	Functional parameters at rest (plethysmography) - assessment of FRC in Liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Inspiratory Capacity (IC) measurement	Functional parameters at rest (plethysmography) - assessment of IC in Liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Residual Volume (RV) measurement	Functional parameters at rest (plethysmography) - assessment of RV in Liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Residual Volume (RV) / Total Lung Capacity (TLC) ratio	Functional parameters at rest (plethysmography) - assessment of ration RV/TLC in Liter	0 Day, 45 Day, 6 month and 12 month
Secondary	Exercise tolerance	6 minutes walking test	0 Day, 45 Day, 6 month and 12 month
Secondary	Quality of life questionnaire	EuroQol 5-Digit 5-level (EQ-5D-5L) questionnaire	0 Day, 45 Day, 6 month and 12 month
Secondary	Quality of life questionnaire	COPD Assessment Test (CAT). Minimum score is 0 and maximum is 40	0 Day, 45 Day, 6 month and 12 month
Secondary	Quality of life questionnaire	Saint-George Respiratory Questionnaire (SGRQ)	0 Day, 45 Day, 6 month and 12 month
Secondary	lobe volume reduction	Target lobe volume reduction by Thorax scanner	45 Day
Secondary	Respiratory events	Study of morbidity and mortality. number of Respiratory events	12 month
Secondary	Events related to the valves	Study of morbidity and mortality. number of events related to the valves	12 month
Secondary	Revision bronchoscopies	Study of morbidity and mortality. Numbers of revision bronchoscopies	12 month
Secondary	Death	Study of morbidity and mortality. numbers of death	12 month
Secondary	responder's rate	In the experimental arm, responder's rate after the first procedure (despite infralobar treatment) defined by: Plethysmography; FEV1: Improvement of equal or more than 12%; RV: Decrease of equal or more than 430mL; Thorax CT scan: target lobe volume reduction rated at more than 350mL.	12 month
Secondary	Incremental Cost-Utility Ratio (ICUR)	Incremental Cost-Utility Ratio (ICUR) of the 2 intervention strategies expressed in euros per QALY gained in 12 months. The ICUR will be calculated on the basis of the following data: Quality of life assessed by the EQ-5D-5L questionnaire. Direct medical costs.	12 month